Alexandre-Raphael Wery, Adriano Salaroli, Fabio Andreozzi, Marianne Paesmans, Laurent Dewispelaere, Pierre Heimann, Sebastian Wittnebel, Philippe Lewalle
{"title":"急性髓性白血病和骨髓增生异常综合征异基因造血干细胞移植前的可测量残留疾病评估:一项为期20年的单中心研究。","authors":"Alexandre-Raphael Wery, Adriano Salaroli, Fabio Andreozzi, Marianne Paesmans, Laurent Dewispelaere, Pierre Heimann, Sebastian Wittnebel, Philippe Lewalle","doi":"10.1007/s00277-024-06017-y","DOIUrl":null,"url":null,"abstract":"<div><p>Patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem-cell transplantation (alloHSCT) can have divergent survival outcomes while all in morphological complete remission (CR). Techniques of measurable residual disease (MRD) have allowed us to refine their prognosis in two categories: MRD-positive and MRD-negative patients. We conducted a monocentric retrospective study (01/2000–12/2020) to assess the prognosis of pretransplant MRD status measured by multiparametric flow cytometry (MFC) and molecular biology assessed by PCR. 192 patients were included. The median follow-up period was 77 months. Among patients undergoing alloHSCT in CR, overall survival (median-OS: 130.6 vs. 16.0 months, <i>P</i> < 0.001), disease-free survival (median-DFS: 109.6 vs. 7.1 months, <i>P</i> < 0.001) and cumulative incidence of relapse (12-month CIR: 7.3% vs. 33.7%, <i>P</i> < 0.0001) were significantly different between MRD-negative and MRD-positive patients. Patients with discordant intermethod results had intermediate DFS. MRD-negative patients according to molecular PCR-based techniques, WT1 overexpression and MFC had longer median-DFS, compared to MRD-positive patients (<i>P</i> = 0.001, <i>P</i> < 0.001, <i>P</i> < 0.001, respectively). Looking into subgroups, MRD-positive patients among the ELN2017 adverse-category (<i>P</i> < 0.0001), myeloablative and reduced-intensity conditioning regimens (<i>P</i> < 0.0001, <i>P</i> = 0.005), < 60-year patients (<i>P</i> < 0.001) and AML patients (<i>P</i> < 0.001) were associated with lower DFS. This difference was not found in ≥ 60-year patients (<i>P</i> = 0.27) and MDS patients (<i>P</i> = 0.70). MRD-positive patients within the favorable/intermediate ELN2017 category trended toward lower DFS (<i>P</i> = 0.05). We confirmed that MRD status prior to alloHSCT is a strong prognostic factor for OS, DFS and CIR. Combining MFC and molecular-PCR techniques to assess MRD seems primordial as inter-method discordance can be consequential.</p></div>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":"103 11","pages":"4671 - 4685"},"PeriodicalIF":3.0000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00277-024-06017-y.pdf","citationCount":"0","resultStr":"{\"title\":\"Measurable residual disease assessment prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes: a 20-year monocentric study\",\"authors\":\"Alexandre-Raphael Wery, Adriano Salaroli, Fabio Andreozzi, Marianne Paesmans, Laurent Dewispelaere, Pierre Heimann, Sebastian Wittnebel, Philippe Lewalle\",\"doi\":\"10.1007/s00277-024-06017-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem-cell transplantation (alloHSCT) can have divergent survival outcomes while all in morphological complete remission (CR). Techniques of measurable residual disease (MRD) have allowed us to refine their prognosis in two categories: MRD-positive and MRD-negative patients. We conducted a monocentric retrospective study (01/2000–12/2020) to assess the prognosis of pretransplant MRD status measured by multiparametric flow cytometry (MFC) and molecular biology assessed by PCR. 192 patients were included. The median follow-up period was 77 months. Among patients undergoing alloHSCT in CR, overall survival (median-OS: 130.6 vs. 16.0 months, <i>P</i> < 0.001), disease-free survival (median-DFS: 109.6 vs. 7.1 months, <i>P</i> < 0.001) and cumulative incidence of relapse (12-month CIR: 7.3% vs. 33.7%, <i>P</i> < 0.0001) were significantly different between MRD-negative and MRD-positive patients. Patients with discordant intermethod results had intermediate DFS. MRD-negative patients according to molecular PCR-based techniques, WT1 overexpression and MFC had longer median-DFS, compared to MRD-positive patients (<i>P</i> = 0.001, <i>P</i> < 0.001, <i>P</i> < 0.001, respectively). Looking into subgroups, MRD-positive patients among the ELN2017 adverse-category (<i>P</i> < 0.0001), myeloablative and reduced-intensity conditioning regimens (<i>P</i> < 0.0001, <i>P</i> = 0.005), < 60-year patients (<i>P</i> < 0.001) and AML patients (<i>P</i> < 0.001) were associated with lower DFS. This difference was not found in ≥ 60-year patients (<i>P</i> = 0.27) and MDS patients (<i>P</i> = 0.70). MRD-positive patients within the favorable/intermediate ELN2017 category trended toward lower DFS (<i>P</i> = 0.05). We confirmed that MRD status prior to alloHSCT is a strong prognostic factor for OS, DFS and CIR. Combining MFC and molecular-PCR techniques to assess MRD seems primordial as inter-method discordance can be consequential.</p></div>\",\"PeriodicalId\":8068,\"journal\":{\"name\":\"Annals of Hematology\",\"volume\":\"103 11\",\"pages\":\"4671 - 4685\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s00277-024-06017-y.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s00277-024-06017-y\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s00277-024-06017-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Measurable residual disease assessment prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndromes: a 20-year monocentric study
Patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem-cell transplantation (alloHSCT) can have divergent survival outcomes while all in morphological complete remission (CR). Techniques of measurable residual disease (MRD) have allowed us to refine their prognosis in two categories: MRD-positive and MRD-negative patients. We conducted a monocentric retrospective study (01/2000–12/2020) to assess the prognosis of pretransplant MRD status measured by multiparametric flow cytometry (MFC) and molecular biology assessed by PCR. 192 patients were included. The median follow-up period was 77 months. Among patients undergoing alloHSCT in CR, overall survival (median-OS: 130.6 vs. 16.0 months, P < 0.001), disease-free survival (median-DFS: 109.6 vs. 7.1 months, P < 0.001) and cumulative incidence of relapse (12-month CIR: 7.3% vs. 33.7%, P < 0.0001) were significantly different between MRD-negative and MRD-positive patients. Patients with discordant intermethod results had intermediate DFS. MRD-negative patients according to molecular PCR-based techniques, WT1 overexpression and MFC had longer median-DFS, compared to MRD-positive patients (P = 0.001, P < 0.001, P < 0.001, respectively). Looking into subgroups, MRD-positive patients among the ELN2017 adverse-category (P < 0.0001), myeloablative and reduced-intensity conditioning regimens (P < 0.0001, P = 0.005), < 60-year patients (P < 0.001) and AML patients (P < 0.001) were associated with lower DFS. This difference was not found in ≥ 60-year patients (P = 0.27) and MDS patients (P = 0.70). MRD-positive patients within the favorable/intermediate ELN2017 category trended toward lower DFS (P = 0.05). We confirmed that MRD status prior to alloHSCT is a strong prognostic factor for OS, DFS and CIR. Combining MFC and molecular-PCR techniques to assess MRD seems primordial as inter-method discordance can be consequential.
期刊介绍:
Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.